U.S. Markets open in 9 hrs 20 mins

Soligenix, Inc. (SNGX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.15+0.05 (+2.38%)
At close: 3:59PM EDT
People also watch
CBLIAPHBFCSCIDXGHTGM
Full screen
Previous Close2.10
Open2.15
Bid2.02 x 500
Ask2.50 x 2000
Day's Range2.10 - 2.20
52 Week Range1.90 - 8.50
Volume29,050
Avg. Volume619,636
Market Cap12.2M
Beta0.11
PE Ratio (TTM)-1.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Soligenix, Inc. :SNGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
    Capital Cube13 days ago

    Soligenix, Inc. :SNGX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Soligenix, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Soligenix, Inc. – Emergent BioSolutions Inc., Cleveland BioLabs, Inc., Johnson & Johnson, Onconova Therapeutics Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Athersys, Inc. (EBS-US, CBLI-US, JNJ-US, ... Read more (Read more...)

  • Zacks Small Cap Research2 months ago

    SNGX: SGX942: Cancer Control is an “Added Bonus” for OM Treatment

    Based on three platform technologies, SNGX has built a diversified pipeline targeting multiple indications. The Company’s oral BDP is in various development stages for a variety of indications, most notably, in pediatric Crohn’s disease, where they will be initiating a Phase III study soon for SGX203.

  • Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
    Capital Cube3 months ago

    Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017

    Categories: Yahoo Finance Get free summary analysis Soligenix, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Soligenix, Inc. – PharmAthene, Inc., Emergent BioSolutions Inc., Cleveland BioLabs, Inc., Sanofi Sponsored ADR, Onconova Therapeutics Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Athersys, Inc. (PIP-US, ... Read more (Read more...)